Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 8:55 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 371 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: androgen deprivation therapy Clear all
Recruiting Phase 2 Interventional

Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery

NCT03541928
View directory record Official record
Conditions
High-risk Prostate Cancer, Prostate Cancer
Interventions
HSV-Tk, Valacyclovir, Bicalutamide, Leuprolide Acetate, Brachytherapy, External beam radiotherapy, Radical prostatectomy
Drug · Radiation · Procedure
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 6, 2021 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

Antiandrogen Withdrawal in Treating Patients With Hormone-Refractory Prostate Cancer

NCT00002760
View directory record Official record
Conditions
Prostate Cancer
Interventions
ketoconazole, therapeutic hydrocortisone, Withdrawal of antiandrogen therapy
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
Up to 120 Years · Male only
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2009
U.S. locations
2
States / cities
San Francisco, California • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 28, 2016 · Synced Oct 7, 2026, 8:55 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

The CArdiovascular Risk Evaluation in Men With Prostate Cancer Study (CARE-PC) Pilot Feasibility Study

NCT06064149
View directory record Official record
Conditions
Prostate Cancer
Interventions
CARE-PC Web-Based Application
Behavioral
Lead sponsor
Vivek Narayan
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Active, not recruiting Phase 3 Interventional

Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial

NCT05050084
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Bicalutamide, Buserelin, Darolutamide, Degarelix, Flutamide, Goserelin, Histrelin, Leuprolide, Radiation Therapy, Relugolix, Triptorelin
Drug · Radiation
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Male only
Enrollment
2,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2031
U.S. locations
567
States / cities
Birmingham, Alabama • Gilbert, Arizona • Peoria, Arizona + 432 more
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional Results available

Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer

NCT03827473
View directory record Official record
Conditions
Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer
Interventions
Abiraterone Acetate, Antiandrogen Therapy, Docetaxel, Prednisone, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2020 · Synced Oct 7, 2026, 8:55 AM EDT
Recruiting Phase 2 Interventional

PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer

NCT06392295
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Hormone Sensitive Prostate Cancer
Interventions
Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy, Androgen Receptor Signaling Inhibitor
Radiation · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older · Male only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 2 Interventional

Antiandrogen Therapy With or Without Axitinib Before Surgery in Treating Patients With Previously Untreated Prostate Cancer With Known or Suspected Lymph Node Metastasis

NCT01409200
View directory record Official record
Conditions
Metastatic Malignant Neoplasm in Lymph Node, Prostate Ductal Adenocarcinoma, Stage III Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Antiandrogen Therapy, Axitinib, Radical Prostatectomy, Regional Lymph Node Dissection
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Terminated Phase 1Phase 2 Interventional

NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma

NCT02805894
View directory record Official record
Conditions
Prostate Cancer
Interventions
NBTXR3 activated by IMRT only, NBTXR3 activated by Brachytherapy & IMRT
Drug
Lead sponsor
Nanobiotix
Industry
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 10, 2021 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Not applicable Interventional

Intensity-Modulated External Beam Radiation Therapy in Treating Patients With Prostate Cancer

NCT01117935
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer
Interventions
intensity modulated external beam radiation therapy
Radiation
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older · Male only
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2019
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 28, 2019 · Synced Oct 7, 2026, 8:55 AM EDT
Recruiting Not applicable Interventional

Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

NCT06172283
View directory record Official record
Conditions
Prostate Cancer
Interventions
Intermittent Fasting
Other
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years and older · Male only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 1Phase 2 Interventional

CP-675,206 With Neoadjuvant Hormone Therapy in Patients With High Risk Prostate Cancer

NCT00075192
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
CP-675,206 and leuprolide acetate and bicalutamide, leuprolide acetate and bicalutamide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
11
States / cities
La Masa, California • Washington D.C., District of Columbia • Gallatin, Tennessee + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2012 · Synced Oct 7, 2026, 8:55 AM EDT
Active, not recruiting Phase 3 Interventional

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer

NCT02446444
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, Conventional NSAA, LHRHA, External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)
Drug · Radiation
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
802 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Not applicable Interventional Results available

Docetaxel, Androgen Deprivation and Proton Therapy for High Risk Prostate Cancer

NCT01040624
View directory record Official record
Conditions
Prostate Cancer
Interventions
> 15% risk of + LN
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 2 Interventional Results available

Bipolar Androgen-based Therapy for Prostate Cancer (BAT)

NCT01750398
View directory record Official record
Conditions
Recurrent Prostate Cancer
Interventions
Testosterone cypionate, Goserelin, Leuprolide
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 7, 2026, 8:55 AM EDT
Terminated No phase listed Observational

Mechanisms of Metabolic and Hormone Action on Plaque Formation in Brain and Carotid Vessels in Patients With Prostate Adenocarcinoma

NCT03718338
View directory record Official record
Conditions
Prostate Adenocarcinoma
Interventions
Evaluation, Quality-of-Life Assessment
Procedure · Other
Lead sponsor
University of Washington
Other
Eligibility
Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 3 Interventional

Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

NCT00067015
View directory record Official record
Conditions
Prostate Cancer
Interventions
bicalutamide, goserelin acetate, assessment of therapy complications, quality-of-life assessment, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2015 · Synced Oct 7, 2026, 8:55 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Strength, Aging, and Memory in Prostate Cancer

NCT04852224
View directory record Official record
Conditions
Prostate Neoplasm, Prostate Cancer
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older · Male only
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 3 Interventional Results available

The Efficacy and Safety of Degarelix One Month Dosing Regimens in Prostate Cancer

NCT00295750
View directory record Official record
Conditions
Prostate Cancer
Interventions
Degarelix, Leuprolide 7.5 mg
Drug
Lead sponsor
Ferring Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
620 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2012 · Synced Oct 7, 2026, 8:55 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Measurement of Anti-Androgen Response Using Fluorine-18 Fluorocholine PET/CT in Androgen-Insensitive Prostate Cancer

NCT00928174
View directory record Official record
Conditions
Prostate Cancer
Interventions
IV administration of fluorine-18 fluorocholine followed by PET/CT imaging
Drug
Lead sponsor
Queen's Medical Center
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Nov 11, 2015 · Synced Oct 7, 2026, 8:55 AM EDT
Recruiting Phase 2 Interventional

Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy

NCT06957691
View directory record Official record
Conditions
Prostate Cancer, Prostate Cancer (Adenocarcinoma), Prostate Cancer Metastatic Disease, Prostate Cancer Recurrent, Prostate Carcinoma, Prostate Neoplasm, Prostate Adenocarcinoma, Prostate Cancer With Bone Metastasis, Vasomotor Disturbance, Vasomotor Symptoms, Vasomotor Symptoms (VMS), Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Vasomotor Symptoms; Hot Flashes, Androgen Deprivation Therapy, Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma, Androgen-deprivation Therapy, Hot Flashes, Hot Flushes, Hot Flushes and/or Sweats
Interventions
fezolinetant - reference formulation, Placebo
Drug
Lead sponsor
Shehzad Basaria, M.D.
Other
Eligibility
40 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Active, not recruiting Not applicable Interventional

Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)

NCT04349501
View directory record Official record
Conditions
Prostate Cancer
Interventions
Restriction Spectrum Imaging Magnetic Resonance Imaging
Other
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Male only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Oct 7, 2026, 8:55 AM EDT
Recruiting Phase 2 Interventional

18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy

NCT05155046
View directory record Official record
Conditions
Localized Prostate Cancer
Interventions
18F-DCFPyL
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Male only
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Recruiting Phase 3 Interventional

Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment

NCT06235697
View directory record Official record
Conditions
Prostate Cancer
Interventions
Radiation, Radiation SBRT only, ADT
Radiation · Drug
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
18 Years and older · Male only
Enrollment
710 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
46
States / cities
Antioch, California • Dublin, California • Fremont, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 7, 2026, 8:55 AM EDT
Terminated Phase 2 Interventional

68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy

NCT04928820
View directory record Official record
Conditions
Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
Computed Tomography, Gallium Ga 68 Gozetotide, Positron Emission Tomography
Procedure · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 21, 2022 · Synced Oct 7, 2026, 8:55 AM EDT